G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection

Philip Keiser, Steven Rademacher, James Smith, Daniel Skiest

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Clarithromycin can ameliorate symptoms and improve survival in disseminated Mycobacterium avium complex (DMAC) infection. Optimal combinations of this drug with other agents remain unknown. Granulocyte colony stimulating factor (G-CSF) is a cytokine that can improve phagocytosis of M. avium complex in vitro. We aim to determine if G-CSF administration is associated with improved survival in patients with DMAC in a retrospective, cohort study. Case records from 1991 to 1995 of 91 patients with DMAC at Parkland Memorial Hospital were reviewed for date of initial DMAC diagnosis, baseline CD4 count, race, sex, antiretroviral use, G-CSF use, therapy for DMAC (clarithromycin, ethambutol, ciprofloxacin and rifabutin) and date of death. Of 91 cases identified, 25 were treated with G-CSF and 66 never received this drug. Baseline characteristics were similar in each group including CD4 count (40 cells/mm3 vs 33 cells/mm3, P = 0.68), clarithromycin use (18 patients vs 52 patients, P = 0.90), and antiretroviral use (20 patients vs 42 patients, P = 0.21). Subjects treated with G-CSF lived longer than those who did not receive this drug (355 days vs 211 days, P < 0.01). In the subgroup treated with clarithromycin, G-CSF. was also associated with increased survival (377 days vs 252 days, P < 0.01). Cox proportional hazards model showed a decreased risk of death in patients treated with G-CSF (RH = 0.22, P < 0.01), clarithromycin (RH = 0.13, P < 0.01) and ethambutol (RH = 0.51, P = 0.02). Ciprofloxacin and rifabutin use did not influence survival. These data support the use of clarithromycin and ethambutol in the treatment of DMAC. Addition of G-CSF to a regimen of clarithromycin and ethambutol may increase survival in DMAC and should be studied prospectively.

Original languageEnglish (US)
Pages (from-to)394-399
Number of pages6
JournalInternational Journal of STD and AIDS
Volume9
Issue number7
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Mycobacterium avium Complex
Granulocyte Colony-Stimulating Factor
Clarithromycin
HIV
Ethambutol
Survival
Infection
Rifabutin
CD4 Lymphocyte Count
Ciprofloxacin
Drug Combinations
Phagocytosis
Proportional Hazards Models
Pharmaceutical Preparations
Cohort Studies
Retrospective Studies
Cytokines
Therapeutics

Keywords

  • Clarithromycin
  • Ethambutol
  • G-CSF
  • Mycobacterium avium complex
  • Survival

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Immunology

Cite this

G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection. / Keiser, Philip; Rademacher, Steven; Smith, James; Skiest, Daniel.

In: International Journal of STD and AIDS, Vol. 9, No. 7, 1998, p. 394-399.

Research output: Contribution to journalArticle

@article{e41bba105b2a449195e153bfbc1a2c88,
title = "G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection",
abstract = "Clarithromycin can ameliorate symptoms and improve survival in disseminated Mycobacterium avium complex (DMAC) infection. Optimal combinations of this drug with other agents remain unknown. Granulocyte colony stimulating factor (G-CSF) is a cytokine that can improve phagocytosis of M. avium complex in vitro. We aim to determine if G-CSF administration is associated with improved survival in patients with DMAC in a retrospective, cohort study. Case records from 1991 to 1995 of 91 patients with DMAC at Parkland Memorial Hospital were reviewed for date of initial DMAC diagnosis, baseline CD4 count, race, sex, antiretroviral use, G-CSF use, therapy for DMAC (clarithromycin, ethambutol, ciprofloxacin and rifabutin) and date of death. Of 91 cases identified, 25 were treated with G-CSF and 66 never received this drug. Baseline characteristics were similar in each group including CD4 count (40 cells/mm3 vs 33 cells/mm3, P = 0.68), clarithromycin use (18 patients vs 52 patients, P = 0.90), and antiretroviral use (20 patients vs 42 patients, P = 0.21). Subjects treated with G-CSF lived longer than those who did not receive this drug (355 days vs 211 days, P < 0.01). In the subgroup treated with clarithromycin, G-CSF. was also associated with increased survival (377 days vs 252 days, P < 0.01). Cox proportional hazards model showed a decreased risk of death in patients treated with G-CSF (RH = 0.22, P < 0.01), clarithromycin (RH = 0.13, P < 0.01) and ethambutol (RH = 0.51, P = 0.02). Ciprofloxacin and rifabutin use did not influence survival. These data support the use of clarithromycin and ethambutol in the treatment of DMAC. Addition of G-CSF to a regimen of clarithromycin and ethambutol may increase survival in DMAC and should be studied prospectively.",
keywords = "Clarithromycin, Ethambutol, G-CSF, Mycobacterium avium complex, Survival",
author = "Philip Keiser and Steven Rademacher and James Smith and Daniel Skiest",
year = "1998",
doi = "10.1258/0956462981922476",
language = "English (US)",
volume = "9",
pages = "394--399",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection

AU - Keiser, Philip

AU - Rademacher, Steven

AU - Smith, James

AU - Skiest, Daniel

PY - 1998

Y1 - 1998

N2 - Clarithromycin can ameliorate symptoms and improve survival in disseminated Mycobacterium avium complex (DMAC) infection. Optimal combinations of this drug with other agents remain unknown. Granulocyte colony stimulating factor (G-CSF) is a cytokine that can improve phagocytosis of M. avium complex in vitro. We aim to determine if G-CSF administration is associated with improved survival in patients with DMAC in a retrospective, cohort study. Case records from 1991 to 1995 of 91 patients with DMAC at Parkland Memorial Hospital were reviewed for date of initial DMAC diagnosis, baseline CD4 count, race, sex, antiretroviral use, G-CSF use, therapy for DMAC (clarithromycin, ethambutol, ciprofloxacin and rifabutin) and date of death. Of 91 cases identified, 25 were treated with G-CSF and 66 never received this drug. Baseline characteristics were similar in each group including CD4 count (40 cells/mm3 vs 33 cells/mm3, P = 0.68), clarithromycin use (18 patients vs 52 patients, P = 0.90), and antiretroviral use (20 patients vs 42 patients, P = 0.21). Subjects treated with G-CSF lived longer than those who did not receive this drug (355 days vs 211 days, P < 0.01). In the subgroup treated with clarithromycin, G-CSF. was also associated with increased survival (377 days vs 252 days, P < 0.01). Cox proportional hazards model showed a decreased risk of death in patients treated with G-CSF (RH = 0.22, P < 0.01), clarithromycin (RH = 0.13, P < 0.01) and ethambutol (RH = 0.51, P = 0.02). Ciprofloxacin and rifabutin use did not influence survival. These data support the use of clarithromycin and ethambutol in the treatment of DMAC. Addition of G-CSF to a regimen of clarithromycin and ethambutol may increase survival in DMAC and should be studied prospectively.

AB - Clarithromycin can ameliorate symptoms and improve survival in disseminated Mycobacterium avium complex (DMAC) infection. Optimal combinations of this drug with other agents remain unknown. Granulocyte colony stimulating factor (G-CSF) is a cytokine that can improve phagocytosis of M. avium complex in vitro. We aim to determine if G-CSF administration is associated with improved survival in patients with DMAC in a retrospective, cohort study. Case records from 1991 to 1995 of 91 patients with DMAC at Parkland Memorial Hospital were reviewed for date of initial DMAC diagnosis, baseline CD4 count, race, sex, antiretroviral use, G-CSF use, therapy for DMAC (clarithromycin, ethambutol, ciprofloxacin and rifabutin) and date of death. Of 91 cases identified, 25 were treated with G-CSF and 66 never received this drug. Baseline characteristics were similar in each group including CD4 count (40 cells/mm3 vs 33 cells/mm3, P = 0.68), clarithromycin use (18 patients vs 52 patients, P = 0.90), and antiretroviral use (20 patients vs 42 patients, P = 0.21). Subjects treated with G-CSF lived longer than those who did not receive this drug (355 days vs 211 days, P < 0.01). In the subgroup treated with clarithromycin, G-CSF. was also associated with increased survival (377 days vs 252 days, P < 0.01). Cox proportional hazards model showed a decreased risk of death in patients treated with G-CSF (RH = 0.22, P < 0.01), clarithromycin (RH = 0.13, P < 0.01) and ethambutol (RH = 0.51, P = 0.02). Ciprofloxacin and rifabutin use did not influence survival. These data support the use of clarithromycin and ethambutol in the treatment of DMAC. Addition of G-CSF to a regimen of clarithromycin and ethambutol may increase survival in DMAC and should be studied prospectively.

KW - Clarithromycin

KW - Ethambutol

KW - G-CSF

KW - Mycobacterium avium complex

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0031822684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031822684&partnerID=8YFLogxK

U2 - 10.1258/0956462981922476

DO - 10.1258/0956462981922476

M3 - Article

C2 - 9696194

AN - SCOPUS:0031822684

VL - 9

SP - 394

EP - 399

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 7

ER -